ELVN Enliven Therapeutics, Inc.
FY2025 10-K
Enliven Therapeutics, Inc. (ELVN) filed its fiscal year 2025 10-K annual report with the SEC on Mar 3, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
- • New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
Management Discussion & Analysis
- • No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
- • Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
Risk Factors
- • FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
- • Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
Get deeper insights on Enliven Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.